Biomarkers in HF: Circulating biomarkers of fibrosis and cardiovascular disease
Circulating biomarkers of fibrosis and cardiovascular disease in patients with heart failure with preserved ejection fraction – analysis of samples collected as part of the PIROUETTE trial
- Hospital – Speciality: Wythenshawe Hospital – Cardiology
- Study type: Study limited to working with human tissue samples and data
- Funder: National Institute for Health and Care Research (NIHR)
Heart failure with preserved ejection fraction (HFpEF) is an unmet need in cardiovascular medicine, with heart muscle scarring (myocardial fibrosis) a key disease mechanism. Muscle scarring can be measured by a MRI scan, but not all patients can undergo this and it’s expensive. Circulating biomarkers in the blood that are sensitive to changes in myocardial fibrosis would represent a cheaper and accessible alternative. This study aims to assess baseline levels of circulating biomarkers relating to fibrosis and cardiovascular disease in gifted samples from patients who were part of the PIROUETTE trial. The study will evaluate the relationship between biomarkers, anti-fibrotic treatment response and other study measures.
Patients with heart failure with preserved ejection fraction (HFpEF).
Participants who were part of the Pirouette study that provided samples.
Study open date and expected length
Opened: 4 May 2023
Expected end date: 1 March 2024
Pending – this study is still active.
Telephone number: 0161 291 3244
Email address: Nicholas.firstname.lastname@example.org
- IRAS number: 320856